Innate Pharma S.A. (IPHA)
| Market Cap | 248.03M |
| Revenue (ttm) | 28.07M |
| Net Income (ttm) | -60.01M |
| Shares Out | 79.75M |
| EPS (ttm) | -0.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 976 |
| Open | 3.11 |
| Previous Close | 3.07 |
| Day's Range | 3.10 - 3.11 |
| 52-Week Range | 2.66 - 11.95 |
| Beta | 0.08 |
| Analysts | Buy |
| Price Target | 9.85 (+216.7%) |
| Earnings Date | Mar 24, 2022 |
About IPHA
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tum...
Financial Performance
In 2021, Innate Pharma's revenue was 24.70 million, a decrease of -64.60% compared to the previous year's 69.77 million. Losses were -52.81 million, -17.47% less than in 2020.
Financial numbers in millions EURFinancial StatementsAnalyst Forecast
According to 10 analysts, the average rating for IPHA stock is "Buy." The 12-month stock price forecast is 9.85, which is an increase of 216.72% from the latest price.
News
Innate Pharma to Participate in Upcoming Investor Conferences
MARSEILLE, France--(BUSINESS WIRE)--Upcoming investor conferences
Innate Pharma Reports First Quarter 2022 Financial Results and Business Update
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma reports first quarter 2022 financial results and business update
Innate Pharma Establishes an At-The-Market (“ATM”) Program on Nasdaq
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it has filed a prospectus supplement with the S...
Innate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tue...
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From Astra...
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) has now dosed...
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 20, 2022
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to hold its Annual General Meeting of shareholders on May 20, 2022
Innate Pharma Files Its 2021 Universal Registration Document (Document d'enregistrement universel) and 2021 Annual Re...
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma files its 2021 universal registration document and 2021 annual report on Form 20-F
Innate Pharma Reports Full Year 2021 Financial Results and Business Update
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma reports Full Year 2021 financial results and business update
Innate Pharma Announces Conference Call and Webcast for Full Year 2021 Financial Results
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for full year 2021 financial results
Innate Pharma Obtains €28.7m in Non-Dilutive Financing in the Form of State Guaranteed Loans
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma obtains €28.7M in non-dilutive financing in the form of State Guaranteed Loans
Innate Pharma: First Patient Dosed in IPH6101/SAR443579 Phase 1/2 Clinical Trial in Various Blood Cancers
MARSEILLE, France--(BUSINESS WIRE)--First patient dosed in IPH6101/SAR443579 Phase 1/2 clinical trial in various blood cancers
Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity
Innate Pharma SA's (NASDAQ: IPHA) data from the Phase 2 expansion cohort (cohort 3) evaluating the monalizumab triplet combination shows preliminary activity and an acceptable safety profile with a low ...
Innate Pharma: Monalizumab Combined With Cetuximab and Durvalumab Demonstrates Anti-Tumor Activity in First-Line Recu...
MARSEILLE, France--(BUSINESS WIRE)--Monalizumab combined with cetuximab and durvalumab demonstrates anti-tumor activity in first-line r/m head and neck cancer at ESMO IO 2021 congress
Innate Pharma to Present Monalizumab Data at ESMO Immuno-Oncology 2021 Congress
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to present monalizumab data at ESMO Immuno-Oncology 2021 Congress
Innate Pharma to Participate in the Evercore ISI 4th Annual HealthConX Virtual Conference
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to participate in the Evercore ISI 4th Annual HealthConX Virtual Conference
Innate Pharma Third Quarter 2021 Report
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma Third Quarter 2021 Report
Innate Pharma Highlights New NK Cell Engager Data With Partner Sanofi at SITC Annual Meeting
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma highlights new NK cell engager data with partner Sanofi at SITC
Innate Pharma Announces Conference Call and Webcast for Q3 2021 Business Update
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tue...
Innate Pharma 2022 Financial Calendar
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2022 financial calendar: March 24, 2022: Publicat...
Here's Why Innate Pharma Stock Is Rocketing Higher Today
A clinical trial with an experimental lung cancer drug produced some positive results.
What Is Happening With Innate Pharma Stock On Friday?
Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Onc...
Monalizumab Data From COAST Trial Presented at ESMO Congress 2021
Marseille, France , Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented r...
Innate Pharma Reports First Half 2021 Financial Results and Business Update
MARSEILLE, France, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six month...
Innate Pharma Announces Conference Call and Webcast for First Half 2021 Business Update
MARSEILLE, France, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on We...
Why Innate Pharma Shares Are Rising On Friday?
Innate Pharma SA (NASDAQ:IPHA) stock closed almost 14% higher on Thursday after the Company disclosed two upcoming presentations scheduled at ESMO 2021 Virtual Congress. The presentations include a late...